SETDB2 and gastric cancer: A recent review reported that low expression of SETDB2 was associated with shorter disease-free survival time in renal cell tumors, while in gastric cancer, SETDB2 overexpression predicted poor prognoses and was associated with tumor progression (Torrano et al., 2019).